MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)

Stopped primary efficacy analysis at Week 24 did not demonstrate non-inferiority of raltegravir versus lopinavir (+) ritonavir

Conditions

• HIV Infection

Interventions

• DRUG: MK0518 (raltegravir)
• DRUG: Comparator: KALETRA™ (lopinavir (+) ritonavir )
• DRUG: Comparator: placebo
• DRUG: Comparator: placebo

Sponsor

Merck Sharp & Dohme LLC